News & Events

• October 3, 2023
  

  C-Path Rare and Orphan Disease Conference Highlights Unprecedented Collaborations and Breakthroughs in Rare Disease Research

  TUCSON, Ariz., October. 3, 2023 — The Critical Path Institute (C-Path) held its highly anticipated Rare and Orphan Disease Conference in September, bringing together leading experts, pharmaceutical industry leaders, regulatory agencies, and patient advocates to have a dynamic dialogue about the latest advancements in rare disease research and drug development. The three-day conference, held at...
• September 12, 2023
  

  C-Path’s Rare Disease Clinical Outcome Assessment Consortium Launches Rare Disease COA Resource

  The Rare Disease COA Resource aims to simplify COA selection for use in rare disease drug development.   TUCSON, Ariz., September 12, 2023 — The Rare Disease Clinical Outcome Assessment (COA) Consortium at Critical Path Institute (C-Path), a public-private partnership focused on optimizing COA selection during drug development for rare diseases, today announced the launch...
• August 15, 2023
  

  NORDs’ IAMRARE Registry Contributes Two New Datasets to C-Path’s RDCA-DAP, Boosting Rare Disease Research and Therapeutic Advancement

  TUCSON, Ariz., August 15, 2023 — Critical Path Institute (C-Path) announced today that the National Organization for Rare Disorders (NORD), a founding partner of the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®), is integrating two new datasets to the platform. The FD/MAS Alliance and A Cure in Sight (ACIS) join five other IAMRARE® registries...
• August 9, 2023
  

  C-Path’s Duchenne Regulatory Science Consortium and Duchenne Data Foundation Announce Collaboration to Advance Solutions for Duchenne Muscular Dystrophy

  TUCSON, Ariz. and VEENENDAAL, Netherlands, August 9, 2023 — Critical Path Institute’s (C-Path) Duchenne Regulatory Science Consortium (D-RSC) and the Duchenne Data Foundation (DDF) are excited to announce a joint collaboration aimed at advancing research and improving healthcare for individuals with Duchenne muscular dystrophy (DMD) and other dystrophinopathies (conditions linked to mutations in the DMD...
• July 19, 2023
  

  The Foundation for Angelman Syndrome Therapeutics to Contribute Data to C-Path’s RDCA-DAP, Accelerating Neurological Disease Research and Therapeutic Development

  TUCSON, Ariz., July 19, 2023 — Critical Path Institute (C-Path) announced today that the Foundation for Angelman Syndrome Therapeutics (FAST), a nonprofit organization dedicated to finding a cure for this genetic disorder, have contributed data from the Global Angelman Syndrome Registry to the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®), managed by C-Path. Angelman...